HIV-1 envelope glycoprotein

Patent metadata

Field	Value
Publication number	US-9738688-B2
Application number	US-201314072209-A
Country	US
Kind code	B2
Filing date	Nov 5, 2013
Priority date	Nov 5, 2012
Publication date	Aug 22, 2017
Grant date	Aug 22, 2017

Abstract

The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron microscopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.

First claim

What is claimed is:

1. An engineered or non-naturally occurring HIV-1 envelope glycoprotein isolated from a BG505 virus and having a SOSIP mutation
wherein the glycoprotein is a BG505 SOSIP.664 gp140 trimer
and
wherein the SOSIP mutation comprises one or more mutations of the wild type amino acid alanine (A) or by wild type amino acid threonine (T) substitution with cysteine (C) (SOS mutation) and/or a mutation of the wild type amino acid isoleucine (I) by substitution with proline (P) (IP mutation);
wherein the BG505 SOSIP.664 gp140 trimer is more compact than a KNH1144 SOSIP.664G trimer isolated from with respect to envelope volume; and
wherein the BG505 SOSIP.664 gp140 trimer has a thermal denaturation midpoint (TM) of about 68 C.

2. An engineered or non-naturally occurring HIV-1 envelope glycoprotein isolated from a BG505 virus and having a SOSIP mutation, wherein the SOSIP mutation comprises a:
(a) mutation of the wild type amino acid threonine (T) by substitution with asparagine (N) to create 2G12, and PGT125, PGT126, PGT127, PGT128, PGT129, PGT130, and/or PGT 131 epitopes;
(b) mutation of the wild type amino acid isoleucine (I) by substitution with proline (P) to facilitation trimerization; or
(c) mutations of the wild type sequence REKR (SEQ ID NO: 1) at amino acid positions by substitution with RRRRRR (SEQ ID NO: 2) to enhance cleavage;
or any combination thereof.

3. An engineered or non-naturally occurring HIV-1 envelope comprising the amino acid sequence of SEQ ID NO: 3.

4. The glycoprotein of claim 1 , wherein the SOSIP mutation comprises a mutation of the wild type amino acid alanine (A) at position 498 of SEQ ID NO: 5 by substitution with cysteine (C) (SOS mutation).

5. The glycoprotein of claim 1 , wherein the SOSIP mutation comprises a mutation of the wild type amino acid threonine (T) at position 602 of SEQ ID NO: 5 by substitution with cysteine (C) (SOS mutation).

6. The glycoprotein of claim 1 , wherein the SOSIP mutation comprises a mutation of the wild type amino acid isoleucine (I) at position 556 of SEQ ID NO: 5 by substitution with proline (P) (IP mutation).

7. The glycoprotein of claim 1 ,
wherein the SOSIP mutation comprises a mutation of the wild type amino acid alanine (A) at position 498 of SEQ ID NO: 5 by substitution with cysteine (C) and of the wild type amino acid threonine (T) at position 602 of SEQ ID NO: 5 by substitution with cysteine (C) (SOS mutation) and a mutation of the wild type amino acid isoleucine (I) at position 556 of SEQ ID NO: 5 by substitution with proline (P) (IP mutation).

8. The glycoprotein of claim 2 , wherein the SOSIP mutation comprises a mutation of the wild type amino acid threonine (T) at position 330 of SEQ ID NO: 5 by substitution with asparagine (N).

9. The glycoprotein of claim 2 , wherein the SOSIP mutation comprises a mutation of the wild type amino acid isoleucine (I) at position 556 of SEQ ID NO: 5 by substitution with proline (P).

10. The glycoprotein of claim 2 , wherein the SOSIP mutation comprises mutations of the wild type sequence REKR (SEQ ID NO: 1) at amino acid positions 505-508 of SEQ ID NO: 5 by substitution with RRRRRR (SEQ ID NO: 2).

11. The glycoprotein of claim 2 , wherein the SOSIP mutation comprises a
(a) mutation of the wild type amino acid threonine (T) at position 330 of SEQ ID NO: 5 by substitution with asparagine (N);
(b) mutation of the wild type amino acid isoleucine (I) at position 556 of SEQ ID NO: 5 by substitution with proline (P); and
(c) mutations of the wild type sequence REKR (SEQ ID NO: 1) at amino acid positions 505-508 of SEQ ID NO: 5 by substitution with RRRRRR (SEQ ID NO: 2).

12. The glycoprotein of claim 3 consisting essentially of the amino acid sequence of SEQ ID NO: 3.

13. The glycoprotein of claim 3 consisting of the amino acid sequence of SEQ ID NO: 3.

14. A method of eliciting an immune response comprising administering to a mammal the glycoprotein of claim 1 .

15. The method of claim 14 further comprising an adjuvant.

16. The method of claim 15 wherein the adjuvant comprises alum.

17. A method of eliciting an immune response comprising administering to a mammal the glycoprotein of claim 3 .

18. The method of claim 17 further comprising an adjuvant.

19. The method of claim 18 wherein the adjuvant comprises alu

Assignees

• Int Aids Vaccine Initiative
• Univ Cornell
• Scripps Research Inst

Inventors

• Caulfield Michael
• Cupo Albert
• Dean Hansi
• Hoffenberg Simon
• King C Richter
• Klasse P J
• Marozsan Andre
• Moore John P
• Sanders Rogier W
• Ward Andrew
• Wilson Ian
• Julien Jean-Philippe

Classifications

• C12N2740/16034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K39/39

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• A61K39/12

  Viral antigens · CPC title

• C12N2740/16122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C07K14/005 Primary

  from viruses · CPC title